Powder: -20°C for 3 years | In solvent: -80°C for 1 year
AS2863619 free base enables the conversion of antigen-specific effector/memory T cells into Foxp3+ regulatory T (Treg) cells. It is a potent, orally active CDK8 and CDK19 inhibitor (IC50s: 0.61 nM and 4.28 nM). STAT5 activation enhanced by AS2863619 free base inhibition of CDK8/19, which consequently activates the Foxp3 gene.
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
25 mg | 約6-8 週間 | ¥ 226,500 |
50 mg | 約6-8 週間 | ¥ 312,500 |
100 mg | 約6-8 週間 | ¥ 427,000 |
1 mL * 10 mM (in DMSO) | 約6-8 週間 | ¥ 87,500 |
説明 | AS2863619 free base enables the conversion of antigen-specific effector/memory T cells into Foxp3+ regulatory T (Treg) cells. It is a potent, orally active CDK8 and CDK19 inhibitor (IC50s: 0.61 nM and 4.28 nM). STAT5 activation enhanced by AS2863619 free base inhibition of CDK8/19, which consequently activates the Foxp3 gene. |
ターゲット&IC50 | CDK19:4.28 nM, CDK8:0.61 nM, STAT5:, GSK-3α:76.67 nM, GSK-3β:63.06 nM |
分子量 | 332.32 |
分子式 | C16H12N8O |
CAS No. | 2241300-50-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 250 mg/mL (752.29 mM), Sonification is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
AS2863619 free base 2241300-50-3 Cell Cycle/Checkpoint CDK AS-2863619 AS-2863619 free base AS 2863619 AS2863619 Inhibitor inhibitor inhibit